Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 394.39
NVAX's Cash to Debt is ranked higher than
55% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. NVAX: 394.39 )
Ranked among companies with meaningful Cash to Debt only.
NVAX' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 394.39

Equity to Asset 0.91
NVAX's Equity to Asset is ranked higher than
85% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NVAX: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
NVAX' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.98
Current: 0.91

0.14
0.98
F-Score: 4
Z-Score: 35.05
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -283.06
NVAX's Operating margin (%) is ranked lower than
65% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. NVAX: -283.06 )
Ranked among companies with meaningful Operating margin (%) only.
NVAX' s 10-Year Operating margin (%) Range
Min: -11502.46   Max: -38.46
Current: -283.06

-11502.46
-38.46
Net-margin (%) -282.72
NVAX's Net-margin (%) is ranked lower than
66% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. NVAX: -282.72 )
Ranked among companies with meaningful Net-margin (%) only.
NVAX' s 10-Year Net-margin (%) Range
Min: -12414.15   Max: -40.49
Current: -282.72

-12414.15
-40.49
ROE (%) -34.28
NVAX's ROE (%) is ranked lower than
55% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. NVAX: -34.28 )
Ranked among companies with meaningful ROE (%) only.
NVAX' s 10-Year ROE (%) Range
Min: -155.17   Max: -26.95
Current: -34.28

-155.17
-26.95
ROA (%) -30.40
NVAX's ROA (%) is ranked lower than
56% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. NVAX: -30.40 )
Ranked among companies with meaningful ROA (%) only.
NVAX' s 10-Year ROA (%) Range
Min: -108.43   Max: -13.76
Current: -30.4

-108.43
-13.76
ROC (Joel Greenblatt) (%) -498.62
NVAX's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. NVAX: -498.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -872.73   Max: -31.47
Current: -498.62

-872.73
-31.47
Revenue Growth (3Y)(%) 2.50
NVAX's Revenue Growth (3Y)(%) is ranked higher than
53% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. NVAX: 2.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 160.4
Current: 2.5

0
160.4
EBITDA Growth (3Y)(%) 32.60
NVAX's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. NVAX: 32.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -58.5   Max: 101.4
Current: 32.6

-58.5
101.4
EPS Growth (3Y)(%) 29.60
NVAX's EPS Growth (3Y)(%) is ranked higher than
85% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NVAX: 29.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.6   Max: 52.3
Current: 29.6

-45.6
52.3
» NVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NVAX Guru Trades in Q2 2014

Paul Tudor Jones 300,000 sh (+902.04%)
First Eagle Investment 500,000 sh (+150.00%)
» More
Q3 2014

NVAX Guru Trades in Q3 2014

First Eagle Investment 500,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q4 2014

NVAX Guru Trades in Q4 2014

First Eagle Investment Sold Out
» More
Q1 2015

NVAX Guru Trades in Q1 2015

Steven Cohen 95,000 sh (New)
Paul Tudor Jones 256,588 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.10
NVAX's P/B is ranked lower than
61% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NVAX: 6.10 )
Ranked among companies with meaningful P/B only.
NVAX' s 10-Year P/B Range
Min: 1.02   Max: 10.71
Current: 6.1

1.02
10.71
P/S 63.10
NVAX's P/S is ranked lower than
83% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. NVAX: 63.10 )
Ranked among companies with meaningful P/S only.
NVAX' s 10-Year P/S Range
Min: 5.93   Max: 99999999.99
Current: 63.1

5.93
99999999.99
Current Ratio 12.17
NVAX's Current Ratio is ranked higher than
81% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. NVAX: 12.17 )
Ranked among companies with meaningful Current Ratio only.
NVAX' s 10-Year Current Ratio Range
Min: 0.44   Max: 37
Current: 12.17

0.44
37
Quick Ratio 12.17
NVAX's Quick Ratio is ranked higher than
82% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NVAX: 12.17 )
Ranked among companies with meaningful Quick Ratio only.
NVAX' s 10-Year Quick Ratio Range
Min: 0.44   Max: 37
Current: 12.17

0.44
37
Days Sales Outstanding 73.65
NVAX's Days Sales Outstanding is ranked lower than
58% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. NVAX: 73.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVAX' s 10-Year Days Sales Outstanding Range
Min: 16.72   Max: 289.75
Current: 73.65

16.72
289.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.30
NVAX's Price/Net Cash is ranked higher than
55% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. NVAX: 8.30 )
Ranked among companies with meaningful Price/Net Cash only.
NVAX' s 10-Year Price/Net Cash Range
Min: 2.48   Max: 193.8
Current: 8.3

2.48
193.8
Price/Net Current Asset Value 8.10
NVAX's Price/Net Current Asset Value is ranked higher than
56% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. NVAX: 8.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVAX' s 10-Year Price/Net Current Asset Value Range
Min: 3.75   Max: 418.8
Current: 8.1

3.75
418.8
Price/Tangible Book 7.20
NVAX's Price/Tangible Book is ranked lower than
59% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. NVAX: 7.20 )
Ranked among companies with meaningful Price/Tangible Book only.
NVAX' s 10-Year Price/Tangible Book Range
Min: 3.01   Max: 187.5
Current: 7.2

3.01
187.5
Price/Median PS Value 1.30
NVAX's Price/Median PS Value is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NVAX: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
NVAX' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 5.8
Current: 1.3

0.09
5.8
Earnings Yield (Greenblatt) -4.60
NVAX's Earnings Yield (Greenblatt) is ranked higher than
58% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. NVAX: -4.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NVAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -169.5   Max: 0
Current: -4.6

-169.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NVV.Germany,
Novavax Inc was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company manages its business as one operating segment: developing recombinant vaccines. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc., Protein Sciences Corporation. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
comment on NVAX Mar 16 2013 
comment on NVAX Mar 16 2013 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
creiter note on NVAX Jan 03 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Reports Second Quarter 2009 Financial Results Aug 07 2009 

More From Other Websites
NOVAVAX INC Financials May 15 2015
Novavax Reports First Quarter 2015 Financial Results May 14 2015
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015 May 14 2015
10-Q for Novavax, Inc. May 09 2015
NOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 08 2015
NOVAVAX INC Files SEC form 10-Q, Quarterly Report May 07 2015
Novavax Reports First Quarter 2015 Financial Results May 07 2015
Q1 2015 Novavax Inc Earnings Release - After Market Close May 07 2015
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015 Apr 30 2015
Russell Rebalancing Will Bring Massive Buy Orders for 5 Key Stocks Apr 29 2015
Zacks Investment Ideas feature highlights: Celladon, Novavax and Bluebird Bio - Press Releases Apr 28 2015
7 Analyst Stocks Under $10 With Massive Upside Calls Apr 11 2015
Novavax to Present at the 14th Annual Needham Healthcare Conference Apr 08 2015
After-hours buzz: Synnex, Dyax, Novavax & more Mar 31 2015
Novavax Announces Closing of Public Offering Mar 31 2015
What Makes Novavax (NVAX) a Strong Sell? - Tale of the Tape Mar 31 2015
Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium... Mar 28 2015
NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Mar 27 2015
Novavax Gives Wall Street Underwriters A Sweet Deal Mar 27 2015
Novavax Prices Public Offering of Common Stock Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK